AIDX Stock — 20/20 Biolabs, Inc. Common Stock

20/20 Biolabs, Inc. Common Stock (AIDX)

Updated October 16, 2026.

AIDX is a Stock. Total return is -98.9% over the past 0.7 years, 111.3 points behind SPY at 12.4%.

20/20 Biolabs, Inc. develops AI-powered blood tests for early detection and prevention of cancers and chronic diseases, offering products including OneTest for Cancer (a multi-cancer early detection test) and OneTest for Longevity (which measures inflammatory biomarkers), while also operating CLIAx, a CLIA laboratory serving overseas diagnostics start-ups. The company does not currently distribute to shareholders. This stock may appeal to investors seeking exposure to early-stage diagnostic and healthcare technology companies, though it carries the risks associated with development-stage businesses.

AIDX performance versus SPY

Price and return data through 2026-10-16.

Total return is -98.9% over the past 0.7 years, 111.3 points behind SPY at 12.4%.

AIDX key facts

Asset type

Stock

Asset class

Equity

Inception date

02/19/2026

Distribution frequency

None

Last close

$0.26 (as of 2026-10-16)

Market cap

$3,327,941

Average volume

188178.0

Beta

-0.425

Payout ratio

0.0%

EPS

$-0.75

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

AIDX risks and drawbacks

Total return has trailed SPY over the available window.

Who may consider AIDX — and who may not

It is a weaker fit for investors who need monthly cash flow (AIDX does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on AIDX

• All tickers starting with A

Tagged: Healthcare.

Frequently asked questions